FROM NEWYORK! asked:


http://finance.yahoo.com/q?s=SCII.OB

It’s having a merger with a japan company. With the completion of the merger, Stem Cell Therapy (OTCBB: SCII), headquartered in Tampa, will have 176 million common shares outstanding, including about 13 million shares that will be issued in the next five days, the release said. Histostem will operate as a wholly owned subsidiary.

The company’s revenue for the past 12 months was $3.8 million and its net income was $600,000 for the same time period, a filing with the Securities and Exchange Commission said. There are 50 employees.

Popularity: 3% [?]

Recent incoming search terms:

• stock jump

Bookmark at: